Kurma Partners has closed its fourth biotech venture capital fund after raising 215 million euros ($252 million) to support ...

Pfizer has abandoned work on a PD-L1-targeting drug that was being tested in patients with various cancers. | Pfizer has ...

While Big Pharmas embarked on a frenzy of acquisitions over recent weeks, Roche’s CEO has explained to Fierce Biotech why the ...

As Sanofi counts down the days before its new leader arrives, the French pharma’s interim CEO acknowledged there had been a ...

Just a few months after ripping up the central nervous system-focused portion of its RIPK1 deal with Rigel Pharmaceuticals, ...

A pair of Sage Therapeutics veterans has launched a neurology-focused startup armed with $106 million and a clinical-stage ...

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution ...

Kyverna Therapeutics has unveiled the full results from its registrational trial of miv-cel in stiff person syndrome (SPS), ...

McKesson let go of a minority share of its medical/surgical solutions division for $1.25 billion to Apollo Funds as part of ...

Roche has shared details of fatalities in its phase 3 relapsing multiple sclerosis (RMS) trials, revealing that deaths from ...

Gene therapy biotech Ray Therapeutics has announced the closing of a $125 million series B financing to support the company’s ...

Following its move to secure ex-China rights to the CD38-directed antibody felzartamab, Biogen is doubling down and building ...